Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | LY3200882 |
| Trade Name | |
| Synonyms | LY 3200882 |
| Drug Descriptions |
LY3200882 is a small molecule that inhibits TGFBR1, potentially resulting in increased anti-tumor immune response and decreased tumor growth (AACR Annual Meeting 2017, Abstract nr 955). |
| DrugClasses | TGFBR1 inhibitor 16 |
| CAS Registry Number | 1898283-02-7 |
| NCIT ID | C132013 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Gemcitabine + LY3200882 + Nab-paclitaxel | Gemcitabine LY3200882 Nab-paclitaxel | 0 | 0 |
| LY3200882 | LY3200882 | 0 | 1 |
| LY3200882 + LY3300054 | LY3200882 LY3300054 | 0 | 0 |
| LY3200882 + Pembrolizumab | LY3200882 Pembrolizumab | 0 | 1 |